Lantern Pharma is trading 5.6% down at $0.67, with broad market pressure after hotter-than-expected inflation data the likeliest explanation. - Major indexes are down more than 0.5%, and inflation-driven pressure has weighed on growth stocks. - No clear company-specific announcement explaining the October 14 decline was identified; the latest company news found was a previously announced October 15 investor conference appearance, not a new catalyst.